Literature DB >> 16778799

High frequency of FGFR3 mutations in adenoid seborrheic keratoses.

Christian Hafner1, Johanna M M van Oers, Arndt Hartmann, Michael Landthaler, Robert Stoehr, Hagen Blaszyk, Ferdinand Hofstaedter, Ellen C Zwarthoff, Thomas Vogt.   

Abstract

FGFR3 germline mutations cause autosomal dominant skeletal disorders including achondroplasia, thanatophoric dysplasia, severe achondroplasia with developmental delay and acanthosis nigricans, and Crouzon syndrome. Somatic mutations of FGFR3 have been identified in bladder cancer, multiple myeloma, and other neoplasms. FGFR3 mutations have also been detected in 40% of seborrheic keratoses (SKs) of the hyperkeratotic and acanthotic subtype, which are very common benign skin tumors. Using a multiplex SNaPshot assay that covers 11 activating FGFR3 mutations, we investigated a series of 27 SKs of the adenoid subtype. Mutations were detected in 23 of 27 (85%) adenoid SKs. R248C mutations were the most frequent mutation type. In two SKs, the A393E mutation was found, which has not been described in acanthotic and hyperkeratotic SKs so far. Three adenoid SKs displayed two simultaneous FGFR3 mutations. Adenoid SKs seem to be characterized by a higher frequency of FGFR3 mutations than hyperkeratotic and acanthotic SKs. The mechanism for the high rate of somatic FGFR3 mutations in these benign skin tumors remains elusive, but UV light exposure may play a potential role, especially in the R248C mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778799     DOI: 10.1038/sj.jid.5700422

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  28 in total

1.  Systemic epidermal nevus with involvement of the oral mucosa due to FGFR3 mutation.

Authors:  Anette Bygum; Christina R Fagerberg; Ole J Clemmensen; Britta Fiebig; Christian Hafner
Journal:  BMC Med Genet       Date:  2011-06-05       Impact factor: 2.103

2.  Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

Authors:  Leopold Groesser; Eva Herschberger; Arno Ruetten; Claudia Ruivenkamp; Enrico Lopriore; Markus Zutt; Thomas Langmann; Sebastian Singer; Laura Klingseisen; Wulf Schneider-Brachert; Agusti Toll; Francisco X Real; Michael Landthaler; Christian Hafner
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

3.  [R248C FGFR3 mutation. Effect on cell growth, apoptosis and attachment in HaCaT keratinocytes].

Authors:  C Hafner; A Hartmann
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

4.  Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.

Authors:  Christian Hafner; Elena López-Knowles; Nuno M Luis; Agustí Toll; Eulàlia Baselga; Alex Fernández-Casado; Silvia Hernández; Adriana Ribé; Thomas Mentzel; Robert Stoehr; Ferdinand Hofstaedter; Michael Landthaler; Thomas Vogt; Ramòn M Pujol; Arndt Hartmann; Francisco X Real
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-02       Impact factor: 11.205

Review 5.  Squamous Cell Cancers: A Unified Perspective on Biology and Genetics.

Authors:  G Paolo Dotto; Anil K Rustgi
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

Review 6.  The duality of human oncoproteins: drivers of cancer and congenital disorders.

Authors:  Pau Castel; Katherine A Rauen; Frank McCormick
Journal:  Nat Rev Cancer       Date:  2020-04-27       Impact factor: 60.716

Review 7.  [Genetic basis of seborrheic keratosis and epidermal nevi].

Authors:  C Hafner; H Hafner; L Groesser
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

Review 8.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

Review 9.  Mosaic RASopathies.

Authors:  Christian Hafner; Leopold Groesser
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

10.  The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects.

Authors:  Sara Ota; Zi-Qiang Zhou; Jason M Link; Peter J Hurlin
Journal:  Hum Mol Genet       Date:  2009-04-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.